Innocan Pharma Posts US$5.25M Q2 Revenue Despite Tariff Uncertainty
Innocan Pharma Corporation reported its second-quarter fiscal year 2026 results, showing revenue of US$5.25M (CAD 7.3M). The company's consumer wellness subsidiary, B.I. Sky Global Ltd., maintained a gross margin of 90.9% during the period.
VALITIC™, the flagship skincare brand of B.I. Sky, continues to hold Amazon's 'Best Seller' badge and remains in its leading position across key product categories on the platform.
Innocan Pharma's CEO, Iris Bincovich, expressed pride in the strength of BI Sky's business and the consumer trust built around their products.
The company's results were impacted by the Trump administration's policies regarding customs duties and tariffs, which created uncertainty and led to a decline in sales. However, Innocan maintains a strong balance sheet and solid liquidity position with approximately US$6.4 million in cash and cash equivalents and US$10.37 million in total assets as of June 30, 2026.